Outputs (2)

A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening (2019)
Presentation / Conference Contribution
Figueredo, G. P., Shi, P., Parkes, A. J., Evans, K., Garibaldi, J. M., Negm, O., Tighe, P. J., Sewell, H. F., & Robertson, J. (2019, June). A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening. Presented at 2019 IEEE Congress on Evolutionary Computation (CEC), Wellington, New Zealand

Current methods to identify cutoff values for tumour-associated molecules (antigens) discrimination are based on statistics and brute force. These methods applied to cancer screening problems are very inefficient, especially with large data sets with... Read More about A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening.

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein (2016)
Journal Article
Alshareeda, A., Negm, O. H., Aleskandarany, M. A., Green, A. R., Nolan, C., Tighe, P. J., Madhusudan, S., Ellis, I. O., & Rakha, E. (2016). Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 159(1), 41-53. https://doi.org/10.1007/s10549-016-3915-8

Impaired DNA damage response (DDR) may play a fundamental role in the pathogenesis of breast cancer (BC). RAD51 is a key player in DNA double-strand break repair. In this study, we aimed to assess the biological and clinical significance of RAD51 exp... Read More about Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.